ReviewActa diabetologica2026
Dietary modulation of the gut microbiota in type 2 diabetes and obesity: mechanisms, interventions, and clinical perspectives.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and type 2 diabetes mellitus (T2DM) are associated with heterogeneous changes in gut microbial composition and function, while mechanistic studies support plausible links among diet, microbial metabolism, intestinal barrier function, immune signaling, and host metabolism. This narrative review integrates diet-microbiome mechanisms, dietary-assessment and multi-omics methodology, major dietary patterns, quantitative clinical intervention evidence, treatment-related microbiome modulation, and implications for precision nutrition. High-fiber, Mediterranean, plant-based, and Western-style dietary patterns can modify microbial functions and metabolites, but responses vary across populations, substrates, baseline microbiota, medications, and study methods. Randomized trials and meta-analyses show selected metabolic effects of dietary and microbiome-targeted interventions; effects are generally modest and heterogeneous, and prebiotics, probiotics, synbiotics, and postbiotics are not interchangeable across products or populations. Medication and procedural exposures can also alter microbiome and metabolome readouts and confound interpretation. Current evidence does not provide a validated basis for routine microbiome-guided pharmacological or surgical treatment selection. Integration of dietary, microbiome, metabolome, and clinical data may identify metabotypes and candidate response patterns, but individualized microbiome-based nutrition remains an emerging, validation-dependent research domain rather than routine clinical practice.
Indexed as
Identifiers
42862338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.